KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBITDA: 2009-2025

Historic EBITDA for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $217.9 million.

  • Halozyme Therapeutics' EBITDA rose 33.53% to $217.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.4 million, marking a year-over-year increase of 54.59%. This contributed to the annual value of $551.5 million for FY2024, which is 63.36% up from last year.
  • Per Halozyme Therapeutics' latest filing, its EBITDA stood at $217.9 million for Q3 2025, which was up 7.65% from $202.4 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year EBITDA high stood at $217.9 million for Q3 2025, and its period low was $34.1 million during Q2 2022.
  • For the 3-year period, Halozyme Therapeutics' EBITDA averaged around $131.9 million, with its median value being $117.2 million (2024).
  • In the last 5 years, Halozyme Therapeutics' EBITDA surged by 1,674.15% in 2021 and then crashed by 63.39% in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' EBITDA stood at $56.5 million in 2021, then skyrocketed by 31.80% to $74.5 million in 2022, then skyrocketed by 35.60% to $101.0 million in 2023, then skyrocketed by 73.70% to $175.5 million in 2024, then soared by 33.53% to $217.9 million in 2025.
  • Its EBITDA was $217.9 million in Q3 2025, compared to $202.4 million in Q2 2025 and $141.5 million in Q1 2025.